BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review
Liye Wang, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Shusen Wang, Fei Xu
Abstract
<b><i>Background:</i></b> The B-Raf proto-oncogene (BRAF<sup>V600E</sup>) gene mutation has been identified in a variety of malignancies, but no evidence of the efficacy of vemurafenib treatment in BRAF<sup>V600E</sup> mutant breast cancer (BC) has been reported. <b><i>Case Presentation:</i></b> We reported a 60-year-old woman with confirmed triple-negative BC with BRAF<sup>V600E</sup> mutation. Progression-free survival (PFS) for first-line chemotherapy was 7 months. The patient received vemurafenib and albumin-bound paclitaxel as second-line therapy, exhibiting regression of some pulmonary metastatic lesions with concomitant progression of other lesions, and achieved 4.4 months of PFS. Genetic testing of the progressed pulmonary lesion revealed the BRAF<sup>V600E</sup> mutation, and acquired new mutations and AR amplification. The patient ultimately died of multiple organ failure and achieved 12 months of overall survival. <b><i>Conclusions:</i></b> The BRAF<sup>V600E</sup> mutation may be a potential prognostic factor and therapeutic target for BC.